Short description
NeuroSense Therapeutics is a clinical-stage drug development company, advancing a groundbreaking treatment for ALS.
Description
NeuroSense Therapeutics Ltd., is a clinical-stage biotechnology company, dedicated to the discovery and development of treatments for debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company's preclinical pipeline includes: (1) StabiliC for the treatment of Parkinson's disease and (2) CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Last funding
Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Herzliya, Tel Aviv, Israel, Asia
Founded on
January 1, 2017
Exited on
December 9, 2021
Went public on
December 9, 2021
Stock symbol
NRSN
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
Blurry Noaccess
Sign in for full access
Founders
Alon Ben-Noon